News

New Subsidiary to Focus on Developing Novel Gene Therapy for Diabetes

Presentation to Highlight the Company’s Gene Therapies for Cancer and Diabetes

Chief Medical Officer Provides Overview of Recent Positive Clinical Patient Outcomes

Demonstrates Prolonged Progression Free Survival of Two Patients in Acclaim-1 and Partial Remission from Maintenance Therapy in Acclaim-3

Expands on the previously granted patents covering the use of REQORSA in combination with immune checkpoint inhibitors

Presentation to Highlight the Company’s Gene Therapies for Cancer and Diabetes

Company Achieves Multiple Clinical Development Milestones in 2024

Presentation to Highlight the Company’s Gene Therapies for Cancer and Diabetes

Expects to Initiate the Phase 2 Expansion Study in the Second Half of 2024